"It won’t surprise you to know that I totally disagree with your...

"It won’t surprise you to know that I totally disagree with your “hunch”." (Apples)

And now my hunch was spot on. It is not going ahead even though this phase II trial has been packaged and sitting there for over a year and half. https://clinicaltrials.gov/ct2/show/NCT02941523?term=nox66&rank=1


What is going ahead is another CEP phase I trial. And first indication of CEP phase II trial not slatted till 2021.

Yet Noxopharm management has predicted that 2018 would be the year registration trial were expected to start

"WE EXPECT TO KNOW BY END OF 2017 OF THE SUCCESS OF OUR MISSION
WE AIM TO BE IN A REGISTRATION STUDY BY END OF 2018"
https://commsec.api.markitondemand....pdf?access_token=DNA8BHPzNVg2Yd83oXDhysro700L


and then they moved it to 2019.

" by the end of this year to have generated clear evidence of the anticancer activity of NOX66, and to have determined the nature of a Phase 3 registration study which we anticipate commencing in 2019.
”https://commsec.api.markitondemand....pdf?access_token=DNA8BHPzNVg2Yd83oXDhysro700L

And today it is now 2021 before the first CEP phase II trial.
Over promising under delivering.
Little wonder the share price has crashed from $1.80 down to below 50c, investors were told they would be in registrations trials by now, and now they will have to wait for two more years just to get to phase II trial.